Segal Kate, Harris Danielle M, Carmone Andy, Haddad Lisa B, Hadigal Sanjay, Hatzold Karin, Jones Chris, Lathrop Eva, Mason Jennifer, Mikulich Meridith
AVAC, Product Introduction and Access, New York, NY, United States.
Catalyst Global, Carlsbad, CA, United States.
Front Reprod Health. 2023 May 22;5:1155948. doi: 10.3389/frph.2023.1155948. eCollection 2023.
The pipeline for multi-purpose prevention technologies includes products that simultaneously prevent HIV, pregnancy and/or other sexually transmitted infections. Among these, the Dual Prevention Pill (DPP) is a daily pill co-formulating oral pre-exposure prophylaxis (PrEP), and combined oral contraception (COC). Clinical cross-over acceptability studies for the DPP require training providers to counsel on a combined product. From February 2021-April 2022, a working group of eight HIV and FP experts with clinical and implementation expertise developed counseling recommendations for the DPP based on existing PrEP/COC guidance.
ASSESSMENT OF POLICY/GUIDELINES OPTIONS AND IMPLICATIONS: The working group conducted a mapping of counseling messages from COC and oral PrEP guidance and provider training materials. Six topics were prioritized: uptake, missed pills, side effects, discontinuation and switching, drug interactions and monitoring. Additional evidence and experts were consulted to answer outstanding questions and counseling recommendations for the DPP were developed. was the topic with the most complexity, raising questions about whether women could "double up" on missed pills or skip the last week of the pack to recover protection faster. required aligning the time to reach protective levels for both DPP components and explaining the need to take DPP pills during week 4 of the pack. The potential intensity of DPP , given the combination of oral PrEP with COC, was an important consideration. looked at managing risk of HIV and unintended pregnancy when stopping or switching from the DPP. Guidance on contended with differing contraindications for COC and PrEP. required balancing clinical requirements with potential user burden.
The working group developed counseling recommendations for the DPP to be tested in clinical acceptability studies. : Take one pill every day for the DPP until the pack is empty. Days 1-21 contain COC and oral PrEP. Days 22-28 do not contain COC to allow for monthly bleeding, but do contain oral PrEP and pills should be taken to maintain HIV protection. Take the DPP for 7 consecutive days to reach protective levels against pregnancy and HIV. : If you miss 1 pill multiple times in a month or 2+ consecutive pills, take the DPP as soon as you remember. Do not take more than 2 pills in a day. If 2+ consecutive pills are missed, only take the last missed pill and discard the other missed pills. : You may experience side effects when you start using the DPP, including changes to monthly bleeding. Side effects are typically mild and go away without treatment. : If you decide to discontinue use of the DPP, but want to be protected from HIV and/or unintended pregnancy, in most cases, you can begin using PrEP or another contraceptive method right away. : There are no drug-drug interactions from combining oral PrEP and COC in the DPP. Certain medications are not recommended due to their contraindication with oral PrEP or COC. : You will need to get an HIV test prior to initiating or restarting the DPP, and every 3 months during DPP use. Your provider may recommend other screening or testing.
Developing recommendations for the DPP as a novel MPT posed unique challenges, with implications for efficacy, cost, and user and provider comprehension and burden. Incorporating counseling recommendations into clinical cross-over acceptability studies allows for real-time feedback from providers and users. Supporting women with information to use the DPP correctly and confidently is critically important for eventual scale and commercialization.
多功能预防技术的产品线包括可同时预防艾滋病毒、怀孕和/或其他性传播感染的产品。其中,双效预防 pill(DPP)是一种每日服用的 pill,它将口服暴露前预防(PrEP)和复方口服避孕药(COC)联合配方。DPP 的临床交叉可接受性研究要求培训提供者就这种联合产品提供咨询。2021 年 2 月至 2022 年 4 月,一个由八名具有临床和实施专业知识的艾滋病毒和计划生育专家组成的工作组根据现有的 PrEP/COC 指南制定了 DPP 的咨询建议。
政策/指南选项及影响评估:该工作组梳理了来自 COC 和口服 PrEP 指南以及提供者培训材料中的咨询信息。确定了六个优先主题:服药率、漏服 pill、副作用、停药和换药、药物相互作用以及监测。咨询了更多证据和专家以回答未解决的问题,并制定了 DPP 的咨询建议。服药率是最复杂的主题,引发了关于女性是否可以“加倍服用”漏服的 pill 或跳过药包的最后一周以更快恢复保护效果的问题。监测需要使 DPP 两种成分达到保护水平的时间保持一致,并解释在药包的第 4 周服用 DPP pill 的必要性。鉴于口服 PrEP 与 COC 的联合使用,DPP 潜在的强度是一个重要考虑因素。停药和换药研究了停止使用 DPP 或从 DPP 换药时如何管理艾滋病毒和意外怀孕的风险。药物相互作用指南涉及 COC 和 PrEP 不同的禁忌症。监测需要在临床要求与潜在的用户负担之间取得平衡。
该工作组制定了 DPP 的咨询建议,以便在临床可接受性研究中进行测试。建议 1:每天服用一粒 DPP,直到药包用完。第 1 - 21 天包含 COC 和口服 PrEP。第 22 - 28 天不包含 COC,以便每月出血,但包含口服 PrEP,应继续服药以维持艾滋病毒保护。连续服用 DPP 7 天以达到预防怀孕和艾滋病毒的保护水平。建议 2:如果您一个月内多次漏服 1 粒 pill 或连续漏服 2 粒及以上 pill,一想起就尽快服用 DPP。一天内服用 pill 不要超过 2 粒。如果连续漏服 2 粒及以上 pill,只服用最后漏服的那粒 pill,并丢弃其他漏服的 pill。建议 3:开始使用 DPP 时您可能会出现副作用,包括月经出血的变化。副作用通常较轻,无需治疗即可消失。建议 4:如果您决定停止使用 DPP,但仍希望预防艾滋病毒和/或意外怀孕,在大多数情况下,您可以立即开始使用 PrEP 或另一种避孕方法。建议 5:DPP 中口服 PrEP 和 COC 联合使用不存在药物相互作用。由于某些药物与口服 PrEP 或 COC 存在禁忌症,因此不建议使用这些药物。建议 6:在开始或重新开始服用 DPP 之前,您需要进行艾滋病毒检测,并且在服用 DPP 期间每 3 个月检测一次。您的医疗服务提供者可能会建议进行其他筛查或检测。
为作为一种新型多功能预防技术的 DPP 制定建议带来了独特的挑战,对疗效、成本以及用户和提供者的理解与负担都有影响。将咨询建议纳入临床交叉可接受性研究可获取来自提供者和用户的实时反馈。为女性提供信息以正确且自信地使用 DPP,对于最终的推广和商业化至关重要。